Your browser doesn't support javascript.
loading
The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu, Qiaoqiao; Deng, Maoxue; Hu, Mei; Liu, Mengna; Chen, Xi; Chen, Yue; Cai, Liang.
Afiliação
  • Shu Q; Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, People's Republic of China.
  • Deng M; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Luzhou, 646000, Sichuan, People's Republic of China.
  • Hu M; Institute of Nuclear Medicine, Southwest Medical University, No. 25, Taiping St., Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
  • Liu M; Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, People's Republic of China.
  • Chen X; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Luzhou, 646000, Sichuan, People's Republic of China.
  • Chen Y; Institute of Nuclear Medicine, Southwest Medical University, No. 25, Taiping St., Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
  • Cai L; School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, People's Republic of China.
Eur J Nucl Med Mol Imaging ; 50(5): 1442-1452, 2023 04.
Article em En | MEDLINE | ID: mdl-36609606
ABSTRACT

PURPOSE:

[18F]FDG PET/CT to detect unknown primary lesions is essential for clinical management but still has limitations. [68Ga]Ga-FAPI is a tumor-stromal imaging agent that provides a promising alternative to [18F]FDG for the assessment of malignancies. We aimed to investigate whether [68Ga]Ga-FAPI PET/CT has an additional role in identifying unknown primary lesions with negative or equivocal [18F] FDG PET/CT results.

METHODS:

This single-center prospective clinical study was conducted between March 2020 and March 2022 at Southwest Medical University Hospital. Patients underwent [18F]FDG PET/CT for the identification of unknown primary lesions. They underwent repeat [68Ga]Ga-FAPI PET/CT when [18F]FDG PET/CT results were negative or equivocal. Histopathological examination, surgery, or clinical follow-up (at least 3 months) for FAPI-positive lesions. The diagnostic efficacy of [68Ga]Ga-FAPI in identifying unknown primary lesions was evaluated.

RESULTS:

A total of 44 participants (median age, 57 ± 12 [SD]; 22 [50%] men) were evaluated. Thirteen of the 44 patients had equivocal [18F]FDG PET/CT findings, while the diagnosis was clear on [68Ga]Ga-FAPI PET/CT. [68Ga]Ga-FAPI PET/CT also revealed primary lesions in additional 17 patients with negative [18F]FDG PET/CT findings. In fourteen of 44 patients, no primary lesion was detected by either tracer. On this basis, we analyzed 94 lymph node metastatic lesions. The mean SUVmax of lymph node metastases on [68Ga] Ga-FAPI PET/CT and [18F]FDG PET/CT were 9.2 ± 5.1, 7.9 ± 4.8 (p = 0.03) and the mean TBR were 9.1 ± 5.2, 4.9 ± 3.1 (p < 0.01), respectively.

CONCLUSION:

[68Ga]Ga-FAPI PET/CT showed great potential for identifying unknown primary lesions and has the potential to improve the detection rate of unknown primary lesions with negative or equivocal for [18F]FDG findings. TRIAL REGISTRATION ClinicalTrial.gov. Identifier ChiCTR2100044131.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias Primárias Desconhecidas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias Primárias Desconhecidas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2023 Tipo de documento: Article